Pay in 4 interest-free payments of $5.48 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
Nonalcoholic steatohepatitis is the most common cause of chronic liver disease in the western countries (up to 24% of all patients with liver disease), with 75% of those with NASH being classified as obese (1)
Thats exactly what researchers discovered with GHK-Cu, a naturally occurring copper peptide now available in advanced therapies like injections, creams, and oral supplements
Study Rationale SURMOUNT-1 Trial Historically, the treatment of obesity focused almost exclusively on lifestyle-based approaches
When a term becomes popular before it becomes medically precise, patients can be left with the impression that a trend is more established than it really is
This leads to a very hot question in the field right now: rebound effect
Tirzepatide under the brand name Mounjaro was developed by Eli Lilly and Company to treat type 2 diabetes, but it quickly gained widespread attention for its effects on weight loss and obesity
